Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration

Gilead Sciences, Inc. announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis (VL). As part of this collaboration, Gilead will donate 380,000 vials of AmBisome(R) (amphotericin B liposome ["]